The exon skipping mutations of the receptor tyrosine kinase MET (METex14), leading to oncogenic MET, are increasingly reported in cancers, including in 3-4% of non-small cell lung cancer (NSCLC). MET
BackgroundEarly diagnosis for α-fetoprotein (AFP) negative hepatocellular carcinoma (HCC) remains a critical problem. Metabolomics is prevalently involved in the identification of novel biomarkers. Th
Background: Although neoadjuvant chemotherapy (NAC) has become the standard treatment option for muscle invasive bladder carcinoma (MIBC), its application is still limited because of the lack of bioma
Metastases in the bone marrow (BM) are grim prognostic factors in patients with neuroblastoma (NB). In spite of extensive analysis of primary tumor cells from high- and low-risk NB patients, a charact
